AdipoPharma Recognized at American Diabetes Association 85th Annual Meeting for PATAS, Its First-in-Class Whole-Body Insulin-Sensitizing CompoundCHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the U.S. and Belgium, was recognized at the American Diabetes Association’s 85th Annual Meeting this week in Chicago for its novel and promising insulin-sensitizing peptide PATAS, set to treat Type 2 diabetes and correct its root cause.
